Skip to main content

Table 1 Patient demographics

From: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Characteristic N = 17
Age, mean (range) years 50 (37–63)
Female 17 (100%)
Race
 Caucasian 9 (57%)
 African–American 8 (43%)
No. prior lines of systemic therapy  
 0 9
 1 4
 2 4
Site of recurrence  
 Locoregional 6
 Distant disease (bone, liver, lung, or brain) 11